Official ESCRS | European Society of Cataract & Refractive Surgeons
London 2014 Registration Visa Letters Programme Satellite Meetings Glaucoma Day 2014 Exhibition Hotel Booking Virtual Exhibition Star Alliance
london escrs

Course handouts are now available
Click here

Come to London


WATCH to find out why

Site updates:

Programme Updates. Programme Overview and - Video Symposium on Challenging Cases now available.


Search Abstracts by author or title
(results will display both Free Papers & Poster)

Is remaining drug effective on diabetic macular edema after breach and storage of a single-use vial of bevacizumab?

Poster Details

First Author: M.Demir TURKEY

Co Author(s):    D. Guven   Z. Acar   D. Ozcan   Y. Sendul   A. Demir  

Abstract Details


To investigate the effect of bevacizumab remaining after withdrawal of the first dose from a single-use vial in macular edema (ME) secondary to diabetic retinopathy (DR).


Sisli Hamidiye Etfal Training and Research Hospital, Department of Ophthalmology


Patients were divided into 4 groups according to duration of storage of the single-use vial of bevacizumab in the refrigerator: Group 1 received IVB when the vial was first opened, and groups 2, 3, and 4 received IVB after 3, 7, and 15 days, respectively, after the first dose or doses had been withdrawn with an insulin (27-gauge) needle from the single-use vial. The Wilcoxon test was used to compare visual acuity (VA) and central macular thickness (CMT) scores before and after treatment.


The mean VA increased significantly and CMT decreased significantly after injection in all groups. No observed serious ophthalmologic or sytemic side effects.


Remaining bevacizumab appeared to be effective for ME secondary to DR. This may be useful for poor countries.

Financial Disclosure:


Back to Poster listing